Promis Neurosciences (NASDAQ:PMN – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $18.00 price target on the stock. HC Wainwright‘s price target suggests a potential upside of 475.08% from the company’s current price.
A number of other analysts have also issued reports on PMN. Chardan Capital set a $20.00 target price on shares of Promis Neurosciences and gave the company a “buy” rating in a research note on Monday, July 27th. Roth Capital cut their price target on shares of Promis Neurosciences to $15.00 and set a “buy” rating on the stock in a report on Monday, November 2nd. Guggenheim reaffirmed a “buy” rating and issued a $69.00 price target (up from $35.00) on shares of Promis Neurosciences in a research note on Tuesday, July 28th. Weiss Ratings lowered shares of Promis Neurosciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Finally, Wall Street Zen raised shares of Promis Neurosciences from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.50.
Get Our Latest Research Report on Promis Neurosciences
Promis Neurosciences Stock Performance
PMN opened at $3.13 on Thursday. The business has a fifty day moving average of $8.58 and a 200 day moving average of $12.46. Promis Neurosciences has a 52-week low of $2.78 and a 52-week high of $27.40.
Promis Neurosciences (NASDAQ:PMN – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.39. On average, analysts expect that Promis Neurosciences will post -4.46 EPS for the current fiscal year.
Insider Buying and Selling at Promis Neurosciences
In other news, Director Eugene Williams bought 26,500 shares of the firm’s stock in a transaction on Wednesday, November 4th. The stock was acquired at an average cost of $3.43 per share, with a total value of $90,895.00. Following the transaction, the director directly owned 40,213 shares in the company, valued at approximately $137,930.59. This trade represents a 193.25% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Neil Cashman bought 10,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were purchased at an average cost of $3.86 per share, with a total value of $38,600.00. Following the completion of the transaction, the insider owned 14,532 shares in the company, valued at $56,093.52. This represents a 220.65% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 37,816 shares of company stock worth $134,746 over the last 90 days. 1.50% of the stock is currently owned by company insiders.
Institutional Trading of Promis Neurosciences
A number of hedge funds have recently added to or reduced their stakes in PMN. Seven Fleet Capital Management LP bought a new position in Promis Neurosciences during the 1st quarter worth about $135,000. ADAR1 Capital Management LLC purchased a new position in Promis Neurosciences during the 1st quarter valued at about $1,211,000. Yu Fan purchased a new position in Promis Neurosciences during the 1st quarter valued at about $4,188,000. Ally Bridge Group NY LLC raised its holdings in shares of Promis Neurosciences by 66.1% in the 1st quarter. Ally Bridge Group NY LLC now owns 414,219 shares of the company’s stock valued at $5,261,000 after purchasing an additional 164,880 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new stake in shares of Promis Neurosciences in the 1st quarter valued at about $16,418,000. 50.13% of the stock is owned by hedge funds and other institutional investors.
About Promis Neurosciences
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company developing antibody-based treatments for neurodegenerative diseases. Its research focuses on misfolded proteins that may contribute to these conditions. The company’s technology is designed to identify disease-associated forms of proteins while distinguishing them from their normally functioning counterparts. Its lead program, PMN310, is an antibody candidate targeting toxic amyloid-beta oligomers for the potential treatment of Alzheimer’s disease.
Recommended Stories
- Five stocks we like better than Promis Neurosciences
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for Promis Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Promis Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
